Lead Product(s) : Acetylcysteine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Glenmark Acquires & Launches Acetylcysteine Injection 6gm/30mL Single-Dose Vials
Details : Glenmark has acquired generic version of Acetadote (acetylcysteine) injection from Aspen Pharma. It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury.
Product Name : Acetadote-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 03, 2025
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspen Announces Local Availability of Lilly’s Mounjaro
Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Product Name : Mounjaro
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Sandoz B2B
Deal Size : $99.9 million
Deal Type : Agreement
Aspen Concludes Two Significant Agreements with Sandoz for China and Europe
Details : The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Product Name : Sandostatin LAR Depot
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
December 04, 2023
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Sandoz B2B
Deal Size : $99.9 million
Deal Type : Agreement
Lead Product(s) : Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Gates Foundation
Deal Size : $30.0 million
Deal Type : Funding
Details : PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.
Product Name : Pneumosil
Product Type : Vaccine
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Gates Foundation
Deal Size : $30.0 million
Deal Type : Funding
Lead Product(s) : 10-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Collaboration
Details : PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countrie...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
August 31, 2022
Lead Product(s) : 10-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children
Details : EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.
Product Name : Eikance
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Partnership
Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa
Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...
Product Name : Trelstar
Product Type : Hormone
Upfront Cash : Undisclosed
February 01, 2022
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ad26.COV2.S
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage
Details : The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : Ad26.COV2.S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Acino Pharma
Deal Size : $119.4 million
Deal Type : Acquisition
Acino Acquires Selected Aspen Brands in South Africa
Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.
Product Name : Trustan
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 22, 2021
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Acino Pharma
Deal Size : $119.4 million
Deal Type : Acquisition
Lead Product(s) : Conjugated Estrogens
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Avion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals
Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...
Product Name : Cenestin
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 12, 2020
Lead Product(s) : Conjugated Estrogens
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Avion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
KEY PRODUCTS
Reset All
Aspen API. More than just an API™
